CHIRALPAK IA IB IC IG

ee >99% RESOLVED

5-10x FASTER THAN HPLC

80-90% LESS SOLVENT

ATROPISOMER SEPARATION

SFC PURIFICATION

SFC Purification Specialists

Complex Molecules Clean Resolutions

Supercritical fluid chromatography for separations other methods can't handle. Chiral resolution, impurity isolation/characterization, and method development for complex pharmaceutical intermediates and building blocks

Start a Project Our Services

What We Do

Three Core Services

Specialized SFC purification and analytical services for pharmaceutical intermediates and building blocks that other methods struggle with.

Impurity Isolation & Characterization

We isolate unknown impurities from your crude drug substance via SFC, then characterize them by NMR and MS. You receive a purified reference standard with full structural identification.

Unknown impurity isolation via preparative SFC
Structural elucidation by NMR and MS
Reference standard with certificate of analysis
ICH Q3A/Q3B impurity profiling support

Chiral & Achiral SFC Purification

Send us your racemic mixture or crude compound. We return separated enantiomers or atropisomers with ee >99% and full analytical characterization.

Chiral screening across 8+ stationary phases
Semi-preparative resolution to >99% ee
Atropisomer separation for axially chiral compounds
Milligram to gram quantities delivered

SFC Method
Development

We develop validated analytical SFC methods for chiral and achiral purity testing to support your regulatory filings — IND, NDA, ANDA.

Chiral purity method development
Achiral impurity profiling methods
Method optimization for speed and resolution
Transfer-ready documentation package

Compound Expertise

Four Target Compound Classes

We specialize in compound classes where SFC delivers genuine advantages over HPLC and crystallization.

// Class 01

Chiral Pharmaceutical Intermediates

Broad chiral resolution capability for kinase inhibitors, CNS compounds, cardiovascular intermediates, and any pharmaceutical requiring enantiopure material. Our full CHIRALPAK immobilized column library covers >95% of chiral separations encountered in drug development.

Published SFC use in ritlecitinib, oliceridine, avapritinib, pralsetinib

// Class 02

Atropisomeric Drug Candidates

When axial chirality defeats HPLC, SFC resolves it. BMS screened 20+ HPLC stationary phases for BMS-986142 — all failed. SFC succeeded. We separate atropisomers for KRAS, BTK, PKMYT1, MCL-1, and PRMT5 inhibitor programs.

Clinical pipeline includes sotorasib, JDQ443, MRTX1719, GDC-6036

// Class 03

Nucleoside Intermediates

SFC purification of modified nucleosides and nucleotide building blocks for oligonucleotide therapeutics. BMS published kilogram-scale SFC purification of STING agonist intermediates — compounds that degraded during HPLC due to silyl migration in protic solvents.

First published kg-scale nucleoside SFC purification (BMS, 2021)

// Class 04

Phosphoramidites & ProTide Intermediates

Phosphoramidite building blocks for oligonucleotide synthesis and ProTide prodrug intermediates. Extremely moisture-sensitive — SFC's anhydrous CO₂ environment protects them during purification. The Sp diastereomer of sofosbuvir is ~18x more potent than the Rp form.

$1.21B phosphoramidite market growing at 8.1% CAGR

Why SFC

The Technology Advantage

Supercritical fluid chromatography uses CO₂-based mobile phases that are faster, greener, and orthogonal to conventional liquid chromatography.

// Speed

5–10x faster cycle times than preparative HPLC. Low-viscosity supercritical CO₂ enables higher flow rates with lower backpressure, dramatically increasing throughput.

// Orthogonal Selectivity

SFC resolves compounds that co-elute on HPLC. The same chiral stationary phase performs fundamentally differently under supercritical conditions — separating what liquid chromatography cannot.

// Green Chemistry

80–90% less organic solvent consumption. CO₂ mobile phase evaporates on depressurization, eliminating solvent removal bottlenecks and reducing environmental impact.

// Gentle Conditions

Non-aqueous, non-protic environment protects moisture-sensitive and thermally labile compounds. Critical for intermediates that degrade during conventional aqueous HPLC processing.

>99%

ee Achieved

CSP Phases

mg–g

Scale Range

Engagement Model

From Sample to Solution

A streamlined pathway from your separation challenge to delivered results.

Consultation

Assess your compound, target specifications, and separation challenge

Screening

Systematic screening across columns and conditions to find optimal separation

Purification

Semi-preparative SFC separation to target purity and ee specifications

Delivery

Purified material with analytical data, CoA, and method documentation

Equipment & Capabilities

Purpose-built for complex pharmaceutical separations that defeat conventional chromatography.

SFC Platform

Semi-preparative SFC with fraction collection, PDA detection, and automated screening capability for rapid method development.

Column Library

Full CHIRALPAK immobilized chiral stationary phase library (IA, IB, IC, IG) plus 12+ achiral columns — C18, silica, diol, amino, cyano, 2-ethylpyridine.

Characterization

NMR and mass spectrometry for structural elucidation, impurity identification, and confirmation of stereochemistry.

Get Started

Initiate Contact

Have a compound that won't crystallize? An atropisomer that HPLC can't resolve? A chiral intermediate that needs enantiopure resolution? Tell us about your separation challenge.

// What to Send Us

Compound structure (or general class if confidential), target purity/ee, quantity needed, and timeline. We'll assess feasibility and provide a proposal within 48 hours.

// Typical Turnaround

Chiral screening: 3–5 business days. Semi-prep purification: 1–2 weeks. Impurity isolation and characterization: 2–4 weeks. Method development: 2–6 weeks.

// Transmit Inquiry

info@kiralitypharma.com

Our team responds within one business day. CDAs available upon request.